An open-label extension trial assessing the safety and tolerability of [S,S]-reboxetine in patients with postherpetic neuralgia (PHN)

Trial Profile

An open-label extension trial assessing the safety and tolerability of [S,S]-reboxetine in patients with postherpetic neuralgia (PHN)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2011

At a glance

  • Drugs Esreboxetine (Primary)
  • Indications Postherpetic neuralgia
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 06 Apr 2011 Actual patient number and end date added, as reported by ClinicalTrials.gov.
    • 17 Jul 2008 Status changed from in progress to discontinued, from clincialtrials.gov record.
    • 09 Aug 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top